Zentalis Pharmaceuticals, Inc. (ZNTL) shareholders
Close on Nov 18, 2026Market cap $97.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Walters William T Joint filing with Walters Group (18.80%), Walters, Susan B. (18.80%) | 17,844,973 | 18.80% | 13G (passive) amendment | Aug 14, 2026 |
| Walters, Susan B. Joint filing with Walters William T (19.70%), Walters Group (19.70%) | 13,509,973 | 19.70% | 13G (passive) amendment | Dec 31, 2025 |
| Walters Group Joint filing with Walters William T (9.10%), Walters, Susan B. (9.10%) | 6,500,000 | 9.10% | 13G (passive) amendment | Jan 21, 2025 |
| Matrix Capital Management Company, LP Joint filing with David E. Goel (9.98%) | 6,459,973 | 9.98% | 13D (active) amendment | Dec 15, 2025 |
| Kush Parmar Joint filing with Andrew J. Schwab (6.40%), 5AM Opportunities II (GP), LLC (5.20%) and 1 more | 4,838,571 | 6.40% | 13G (passive) | Dec 18, 2025 |
| Robin C. John Joint filing with Eventide Asset Management, LLC (6.28%), Finny Kuruvilla, M.D., Ph. D. (6.28%) | 4,475,054 | 6.28% | 13G (passive) amendment | Dec 31, 2024 |
| Matthew Sesterhenn Joint filing with Squadron Master Fund LP (5.10%), Squadron Capital Management LLC (5.10%) and 1 more | 3,676,900 | 5.10% | 13G (passive) | Feb 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZNTL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | 5.51% | $19.15M | – | 6.65% |
| BlackRock, Inc. | 3,753,525 | 5.24% | $18.20M | +2,483,688 | 0.00% |
| Squadron Capital Management LLC | 3,700,000 | 5.16% | $17.95M | +69,000 | 5.57% |
| Two Sigma Investments, LP | 3,024,936 | 4.22% | $14.67M | +68,410 | 0.01% |
| Vanguard Capital Management LLC | 2,835,669 | 3.96% | $13.75M | +524,962 | 0.00% |
| Acadian Asset Management LLC | 2,681,900 | 3.74% | $13.00M | −166,352 | 0.02% |
| Citadel Advisors LLC | 2,298,403 | 3.21% | $11.15M | +566,320 | 0.00% |
| Renaissance Technologies LLC | 1,609,078 | 2.25% | $7.80M | −329,067 | 0.01% |
| Opaleye Management Inc. | 1,412,656 | 1.97% | $6.85M | – | 0.62% |
| Orbimed Advisors LLC | 1,390,576 | 1.94% | $6.74M | New | 0.12% |
| Decheng Capital LLC | 1,323,327 | 1.85% | $6.42M | – | 0.88% |
| Geode Capital Management, LLC | 1,284,117 | 1.79% | $6.23M | +663,081 | 0.00% |
| Bank Of America Corp /De/ | 1,114,650 | 1.56% | $5.41M | −17,644 | 0.00% |
| Ishara Investments LP | 1,025,000 | 1.43% | $4.97M | −205,000 | 3.65% |
| Primecap Management Co/Ca/ | 957,420 | 1.34% | $4.64M | – | 0.00% |
| Pfizer Inc | 953,834 | 1.33% | $3.85M | – | 2.26% |
| Soleus Capital Management, L.P. | 950,000 | 1.33% | $4.61M | New | 0.16% |
| State Street Corp | 887,416 | 1.24% | $4.30M | +637,726 | 0.00% |
| Vanguard Portfolio Management LLC | 808,548 | 1.13% | $3.92M | +447,948 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 758,033 | 1.06% | $3.68M | −33,968 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 114 | 47M | 66.1% | 34 / 29 | 32 / 19 | 11M | 7M |
| Q1 2026 | 102 | 44M | 60.8% | 27 / 30 | 28 / 10 | 12M | 6M |
| Q4 2025 | 86 | 41M | 56.7% | 8 / 28 | 31 / 18 | 9M | 21M |
| Q3 2025 | 99 | 54M | 75.3% | 5 / 36 | 33 / 23 | 7M | 9M |
| Q2 2025 | 117 | 56M | 77.6% | 22 / 34 | 44 / 37 | 8M | 11M |
| Q1 2025 | 132 | 58M | 81.6% | 18 / 42 | 50 / 27 | 11M | 16M |
| Q4 2024 | 142 | 64M | 89.9% | 33 / 56 | 32 / 24 | 9M | 16M |
| Q3 2024 | 136 | 71M | 99.7% | 27 / 45 | 39 / 35 | 12M | 13M |
| Q2 2024 | 145 | 77M | 100.0% | 26 / 55 | 43 / 21 | 8M | 19M |
| Q1 2024 | 142 | 87M | 100.0% | 36 / 44 | 37 / 14 | 9M | 4M |
| Q4 2023 | 120 | 82M | 100.0% | 20 / 45 | 32 / 36 | 15M | 11M |
| Q3 2023 | 137 | 80M | 100.0% | 17 / 52 | 39 / 13 | 4M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
75 funds held ZNTL in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ZNTL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,187,299 | 3.05% | $10.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,238,686 | 1.73% | $6.01M | 0.01% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 676,400 | 0.94% | $3.21M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 575,846 | 0.80% | $2.79M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 545,843 | 0.76% | $2.59M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 453,857 | 0.63% | $2.20M | 0.02% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 320,460 | 0.45% | $1.55M | 0.05% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 264,189 | 0.37% | $1.28M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 263,826 | 0.37% | $1.06M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 165,303 | 0.23% | $801.72K | 0.05% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 154,468 | 0.22% | $732.18K | 0.00% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 150,598 | 0.21% | $602.39K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 121,689 | 0.17% | $576.81K | 0.01% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 113,655 | 0.16% | $538.72K | 0.02% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 99,589 | 0.14% | $398.36K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Julia Marie Eastland | CEO & President, Director | 79,133 | 0.11% | Feb 10, 2026 |
| Ingmar Bruns | Chief Medical Officer | 43,059 | 0.06% | Oct 1, 2026 |
| Vincent Vultaggio | PAO and PFO | 146,506 | 0.20% | Feb 10, 2026 |
| James B. Bucher | Chief Legal Officer | – | – | Jan 9, 2026 |
| Mark Lackner | Chief Scientific Officer | 512,856 | 0.72% | Feb 5, 2025 |
| Andrea Paul | Chief Legal Officer | 1,070,784 | 1.49% | Feb 5, 2025 |
| Enoch Kariuki | Director | 194,465 | 0.27% | Jun 18, 2026 |
| Jan Skvarka | Director | 264,254 | 0.37% | Jun 18, 2026 |
| Luke Nathaniel Walker | Director | 201,384 | 0.28% | Jun 18, 2026 |
| Scott Dunseth Myers | Director | 395,895 | 0.55% | Jun 18, 2026 |
| David Michael Johnson | Director | 307,521 | 0.43% | Jun 18, 2026 |
| Shannon Campbell | Director | 114,200 | 0.16% | May 27, 2026 |
| William Thurman Walters | 10% owner | 17,844,973 | 24.90% | Aug 19, 2026 |
| Group Walters | 10% owner | – | – | Aug 19, 2026 |
| Susan Berkley Walters | 10% owner | – | – | Aug 19, 2026 |
| David E. Goel | 10% owner | 6,459,973 | 9.01% | Dec 15, 2025 |
| Matrix Capital Management Company, LP | 10% owner | 13,959,973 | 19.48% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ingmar Bruns Chief Medical Officer | Sep 30, 2026 | Award | +9,727 | $2.18 | $21.20K | 43,059 |
| William Thurman Walters 10% owner | Aug 14, 2026 | Buy | +4,335,000 | $3.50 | $15.17M | 17,844,973 |
| Enoch Kariuki Director | Jun 16, 2026 | Award | +57,100 | – | – | 194,465 |
| Jan Skvarka Director | Jun 16, 2026 | Award | +57,100 | – | – | 264,254 |
| David Michael Johnson Director | Jun 16, 2026 | Award | +57,100 | – | – | 307,521 |
| Scott Dunseth Myers Director | Jun 16, 2026 | Award | +57,100 | – | – | 395,895 |
| Luke Nathaniel Walker Director | Jun 16, 2026 | Award | +57,100 | – | – | 201,384 |
| Shannon Campbell Director | May 26, 2026 | Award | +114,200 | – | – | 114,200 |
| Vincent Vultaggio PAO and PFO | Feb 10, 2026 | Sale(10b5-1 plan) | −6,894 | $2.42 | $16.68K | 146,506 |
| Vincent Vultaggio PAO and PFO | Feb 9, 2026 | Sale(10b5-1 plan) | −3,379 | $2.39 | $8.08K | 153,400 |
| Ingmar Bruns Chief Medical Officer | Feb 9, 2026 | Sale | −335 | $2.39 | $801 | 33,332 |
| Julia Marie Eastland CEO & President, Director | Feb 9, 2026 | Sale | −889 | $2.39 | $2.12K | 79,133 |
| Vincent Vultaggio PAO and PFO | Feb 6, 2026 | Sale(10b5-1 plan) | −29,951 | $2.43 | $72.78K | 156,779 |
| Ingmar Bruns Chief Medical Officer | Feb 6, 2026 | Sale | −2,962 | $2.43 | $7.20K | 33,667 |
| Julia Marie Eastland CEO & President, Director | Feb 6, 2026 | Sale | −7,866 | $2.43 | $19.11K | 80,022 |
| Vincent Vultaggio PAO and PFO | Feb 3, 2026 | Sale(10b5-1 plan) | −556 | $2.52 | $1.40K | 186,730 |
| Vincent Vultaggio PAO and PFO | Feb 2, 2026 | Sale(10b5-1 plan) | −2,540 | $2.55 | $6.48K | 187,286 |
| William Thurman Walters 10% owner | Dec 31, 2025 | Buy | +6,459,973 | $1.20 | $7.75M | 13,509,973 |
| David E. Goel 10% owner | Dec 15, 2025 | Sale | −7,500,000 | $1.33 | $9.98M | 6,459,973 |
| David Michael Johnson Director | Jun 17, 2025 | Award | +57,603 | – | – | 250,421 |
| Enoch Kariuki Director | Jun 17, 2025 | Award | +57,603 | – | – | 137,365 |
| Jan Skvarka Director | Jun 17, 2025 | Award | +57,603 | – | – | 207,154 |
| Scott Dunseth Myers Director | Jun 17, 2025 | Award | +57,603 | – | – | 338,795 |
| Luke Nathaniel Walker Director | Jun 17, 2025 | Award | +57,603 | – | – | 144,284 |
| Scott Dunseth Myers Director | Apr 30, 2025 | Buy | +21,000 | $1.40 | $29.40K | 281,192 |
| Ingmar Bruns Chief Medical Officer | Feb 6, 2025 | Buy | +20,000 | $2.28 | $45.60K | 36,629 |
| Mark Lackner Chief Scientific Officer | Feb 3, 2025 | Sale | −14,368 | $1.71 | $24.57K | 512,856 |
| Mark Lackner Chief Scientific Officer | Feb 3, 2025 | Award | +335,907 | – | – | 527,224 |
| Julia Marie Eastland CEO & President, Director | Feb 3, 2025 | Award | +59,388 | – | – | 87,888 |
| Andrea Paul Chief Legal Officer | Feb 3, 2025 | Sale | −13,230 | $1.71 | $22.62K | 1,070,784 |
| Andrea Paul Chief Legal Officer | Feb 3, 2025 | Award | +934,041 | – | – | 1,084,014 |
| Ingmar Bruns Chief Medical Officer | Feb 3, 2025 | Award | +16,629 | – | – | 16,629 |
| Vincent Vultaggio PAO and Interim PFO | Feb 3, 2025 | Sale | −2,615 | $1.71 | $4.47K | 189,826 |
| Vincent Vultaggio PAO and Interim PFO | Feb 3, 2025 | Award | +158,586 | – | – | 192,441 |
| Jan Skvarka Director | Jan 31, 2025 | Buy | +60,000 | $1.72 | $103.20K | 149,551 |
| Julia Marie Eastland CEO & President, Director | Jan 31, 2025 | Buy | +28,500 | $1.73 | $49.31K | 28,500 |
| Luke Nathaniel Walker Director | Jan 31, 2025 | Buy | +14,200 | $1.76 | $24.99K | 86,681 |
| Mark Lackner Chief Scientific Officer | Jan 2, 2025 | Sale | −4,411 | $3.12 | $13.76K | 191,317 |
| Scott Dunseth Myers Director | Nov 13, 2024 | Award | +260,192 | – | – | 260,192 |
| Vincent Vultaggio Principal Accounting Officer | Oct 4, 2024 | Sale(10b5-1 plan) | −1,603 | $3.18 | $5.10K | 33,855 |
| Enoch Kariuki Director | Jun 21, 2024 | Award | +41,581 | – | – | 79,762 |
| David Michael Johnson Director | Jun 21, 2024 | Award | +48,429 | – | – | 192,818 |
| Jan Skvarka Director | Jun 21, 2024 | Award | +41,581 | – | – | 89,551 |
| Cam Gallagher President, Interim CFO, Director | May 31, 2024 | Sale(10b5-1 plan) | −9,597 | $11.98 | $114.97K | 633,680 |
| Luke Nathaniel Walker Director | May 24, 2024 | Award | +72,481 | – | – | 72,481 |
| Diana Hausman Chief Medical Officer | May 9, 2024 | Sale | −3,356 | $12.62 | $42.35K | 373,876 |
| Cam Gallagher President, Director | Feb 12, 2024 | Sale(10b5-1 plan) | −1,173 | $11.44 | $13.42K | 643,277 |
| Epperly Melissa B, Chief Financial Officer | Feb 12, 2024 | Sale(10b5-1 plan) | −2,573 | $11.44 | $29.44K | 451,449 |
| Epperly Melissa B, Chief Financial Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −8,669 | $11.54 | $100.04K | 454,022 |
| Cam Gallagher President, Director | Feb 2, 2024 | Sale(10b5-1 plan) | −11,552 | $11.54 | $133.31K | 644,450 |
| Mark Lackner Chief Scientific Officer | Feb 2, 2024 | Sale | −1,585 | $11.54 | $18.29K | 195,728 |
| Andrea Paul Chief Legal Officer | Feb 2, 2024 | Sale | −3,310 | $11.54 | $38.20K | 149,973 |
| Diana Hausman Chief Medical Officer | Feb 1, 2024 | Award | +337,500 | – | – | 377,232 |
| Epperly Melissa B, Chief Financial Officer | Feb 1, 2024 | Award | +75,000 | – | – | 462,691 |
| Cam Gallagher President, Director | Feb 1, 2024 | Award | +192,500 | – | – | 656,002 |
| Mark Lackner Chief Scientific Officer | Feb 1, 2024 | Award | +141,000 | – | – | 197,313 |
| Kimberly Blackwell Chief Executive Officer, Director | Feb 1, 2024 | Tax withholding | −20,655 | $11.69 | $241.46K | 484,145 |
| Kimberly Blackwell Chief Executive Officer, Director | Feb 1, 2024 | Award | +250,000 | – | – | 504,800 |
| Andrea Paul Chief Legal Officer | Feb 1, 2024 | Award | +112,500 | – | – | 153,283 |
| Mark Lackner Chief Scientific Officer | Jan 2, 2024 | Award | +40,000 | – | – | 56,313 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Zentalis Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,398 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cam Gallagher Former Director, Former President & Interim CFO | Feb 11, 2025 | 687 | $1.37K | Feb 11, 2025 | Restricted Stock Unit Release |
| Mark Lackner Chief Scientific Officer | Feb 3, 2025 | 14,368 | $24.59K | Feb 3, 2025 | Restricted Stock Unit Release |
| Andrea Paul Chief Legal Officer & Corporate Secretary | Feb 3, 2025 | 13,230 | $22.64K | Feb 3, 2025 | Restricted Stock Unit Release |
| Cam Gallagher Former Director, Former President & Interim CFO | Feb 3, 2025 | 28,558 | $48.88K | Feb 3, 2025 | Restricted Stock Unit Release |
| Diana Hausman Former Chief Medical Officer | Oct 31, 2024 | 9,888 | $28.29K | Oct 31, 2024 | Restricted Stock Unit Release |
| Cam Gallagher Director, Officer - President & Interim CFO | May 31, 2024 | 9,597 | $114.98K | May 31, 2024 | Restricted Stock Unit Release |
| Diana Hausman Chief Medical Officer | May 9, 2024 | 3,356 | $42.36K | May 9, 2024 | Restricted Stock Unit Release |
| Epperly Melissa B, Chief Financial Officer | Feb 12, 2024 | 2,573 | $29.42K | Feb 12, 2024 | Restricted Stock Unit Release |
| Kevin D. Bunker Former Chief Scientific Officer | Feb 12, 2024 | 5,478 | $62.64K | Feb 12, 2024 | Restricted Stock Unit Release |
| Cam Gallagher President, Director | Feb 12, 2024 | 1,173 | $13.41K | Feb 12, 2024 | Restricted Stock Unit Release |
| Carrie Brownstein Former Chief Medical Officer | Feb 2, 2024 | 2,059 | $23.76K | Feb 2, 2024 | Restricted Stock Unit Release |
| Epperly Melissa B, Chief Financial Officer | Feb 2, 2024 | 8,669 | $100.02K | Feb 2, 2024 | Restricted Stock Unit Release |
| Cam Gallagher President, Director | Feb 2, 2024 | 11,552 | $133.28K | Feb 2, 2024 | Restricted Stock Unit Release |
| Andrea Paul Chief Legal Officer and Corporate Secretary | Feb 2, 2024 | 3,310 | $38.19K | Feb 2, 2024 | Restricted Stock Unit Release |
| Kevin D. Bunker Former Chief Scientific Officer | Feb 2, 2024 | 11,109 | $128.17K | Feb 2, 2024 | Restricted Stock Unit Release |
See a number that looks wrong?